1990
RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination
Mane S, Meltzer S, Gutheil J, Kapil V, Lee E, Needleman S. RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination. Genes Chromosomes And Cancer 1990, 2: 71-77. PMID: 2278967, DOI: 10.1002/gcc.2870020113.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceCohort StudiesDNA Mutational AnalysisDNA, NeoplasmExonsGene Expression Regulation, NeoplasticGenes, rasHumansIatrogenic DiseaseLeukemia, Myeloid, AcuteMolecular Sequence DataPolymerase Chain ReactionProspective StudiesProto-Oncogene Proteins p21(ras)Transcriptional ActivationConceptsAcute myeloid leukemia patientsMaryland Cancer CenterMyeloid leukemia patientsAcute myelogenous leukemiaRAS gene activationProspective cohortCancer CenterLeukemia patientsPrecise prevalenceMyelogenous leukemiaNRAS mutationsRAS activationRAS mutationsGene point mutationsBiologic parametersLarger studyHuman cancersPatientsAMLProtooncogene activationExon mutationsActivationCell DNAMutationsPoint mutations
1989
c-myc amplification coexistent with activating N-ras point mutation in the biphenotypic leukemic cell line RED-3.
Mallet M, Mane S, Meltzer S, Needleman S. c-myc amplification coexistent with activating N-ras point mutation in the biphenotypic leukemic cell line RED-3. Leukemia 1989, 3: 511-5. PMID: 2659902.Peer-Reviewed Original ResearchConceptsCell linesMYC activationAcute myelogenous leukemiaN-ras point mutationsActivating point mutationC-MycN-rasAML patientsAcute leukemiaHL-60AML cellsMyelogenous leukemiaAggressive acute leukemiasLineage infidelityHuman tumorsDerivative cell linesPoint mutationsPatientsLeukemiaActivationSmall proportionCellsRed 3Protooncogene cMalignancy